The Emerging Role of Inhaled Heroin in the Opioid Epidemic
- 1 November 2018
- journal article
- review article
- Published by American Medical Association (AMA) in JAMA Neurology
- Vol. 75 (11) , 1423-1434
Abstract
Importance Opioid addiction affects approximately 2.4 million Americans. Nearly 1 million individuals, including a growing subset of 21 000 minors, abuse heroin. Its annual cost within the United States amounts to $51 billion. Inhaled heroin use represents a global phenomenon and is approaching epidemic levels east of the Mississippi River as well as among urban youth. Chasing the dragon (CTD) by heating heroin and inhaling its fumes is particularly concerning, because this method of heroin usage has greater availability, greater ease of administration, and impressive intensity of subjective experience (high) compared with sniffing or snorting, although it also has a safer infectious profile compared with heroin injection. This is relevant owing to peculiar and often catastrophic brain complications. Following the American Medical Association Opioid Task Force mandate, we contribute a description of the pharmacology, pathophysiology, clinical spectrum, neuroimaging, and neuropathology of CTD leukoencephalopathy, as distinct from other heroin abuse modalities. Observations The unique spectrum of CTD-associated health outcomes includes an aggressive toxic leukoencephalopathy with pathognomonic neuropathologic features, along with sporadic instances of movement disorders and hydrocephalus. Clinical CTD severity is predominantly moderate at admission, frequently unmodified at discharge, and largely improved in the long term. Mild cases survive with minor sequelae, while moderate to severe presentations might deteriorate and progress to death. Other methods of heroin use may complicate with stroke, seizure, obstructive hydrocephalus, and (uncharacteristically) leukoencephalopathy. Conclusions and Relevance The distinct pharmacology of CTD correlates with its specific clinical and radiological features and prompts grave concern for potential morbidity and long-term disability costs. Proposed diagnostic criteria and standardized reporting would ameliorate the limitations of CTD literature and facilitate patient selection for a coenzyme Q10 therapeutic trial.Keywords
This publication has 131 references indexed in Scilit:
- Progressive White Matter Microstructure Damage in Male Chronic Heroin Dependent Individuals: A DTI and TBSS StudyPLOS ONE, 2013
- Developing clinical practice guidelines: types of evidence and outcomes; values and economics, synthesis, grading, and presentation and deriving recommendationsImplementation Science, 2012
- Morphine metabolism, transport and brain dispositionMetabolic Brain Disease, 2011
- Comparing Injection and Non-Injection Routes of Administration for Heroin, Methamphetamine, and Cocaine Users in the United StatesJournal of Addictive Diseases, 2011
- Chasing the dragon - characterizing cases of leukoencephalopathy associated with heroin inhalation in British ColumbiaHarm Reduction Journal, 2011
- AGREE II: advancing guideline development, reporting and evaluation in health careCanadian Medical Association Journal, 2010
- Heroin in brown, black and white: Structural factors and medical consequences in the US heroin marketInternational Journal of Drug Policy, 2009
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendationsBMJ, 2008
- Distributing foil from needle and syringe programmes (NSPs) to promote transitions from heroin injecting to chasing: An evaluationHarm Reduction Journal, 2008
- Acute myelopathy selectively involving lumbar anterior horns following intranasal insufflation of ecstasy and heroinJournal of Neurology, Neurosurgery & Psychiatry, 2007